Richard Leach, DO
Internal Medicine · East Greenwich, RINPI 1407852155
Payments from drug & device makers
Across 243 payments — averaging $13.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$607
- AbbVie$389
- Boehringer Ingelheim$336
- AstraZeneca$317
- Amgen$284
- Lilly USA, LLC$242
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,370100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 55 | $607 |
| AbbVie(2 entities) | 25 | $389 |
| Boehringer Ingelheim | 20 | $336 |
| AstraZeneca | 21 | $317 |
| Amgen | 15 | $284 |
| Lilly USA, LLC | 19 | $242 |
| Johnson & Johnson | 17 | $239 |
| E.r. Squibb & Sons, L.L.C. | 13 | $230 |
| Merck | 21 | $128 |
| Sanofi-aventis U.S. LLC | 6 | $106 |
| Exact Sciences | 5 | $91 |
| Sunovion Pharmaceuticals Inc. | 5 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| Ironwood Pharmaceuticals, Inc | 3 | $54 |
| GSK | 3 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Novartis | 1 | $21 |
| Abbott | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Lupin Inc. | 1 | $13 |
How this compares
$3,379 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $114,519 |
| TrulicityDulaglutide | 72 | $82,994 |
| JardianceEmpagliflozin | 103 | $81,221 |
| OzempicSemaglutide | 52 | $50,367 |
| XareltoRivaroxaban | 21 | $34,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,999 |
| JanuviaSitagliptin Phosphate | 22 | $17,457 |
| Atorvastatin Calcium | 732 | $8,641 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $7,907 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $6,658 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $6,644 |
| Lisinopril | 552 | $5,695 |
| Omeprazole | 365 | $5,686 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,513 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 14 | $4,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $607 | $115,949168 claims |
| Lilly USA, LLCTrulicity | $242 | $82,99472 claims |
| Boehringer IngelheimJardiance | $336 | $81,221103 claims |
| Novo NordiskOzempic | $20 | $50,36752 claims |
| Johnson & JohnsonXarelto | $239 | $34,27921 claims |
| GSKTrelegy Ellipta | $44 | $23,99936 claims |
| MerckJanuvia | $128 | $17,45722 claims |
| AbbVieNamzaric, Synthroid | $389 | $8,23437 claims |
| AstraZenecaSymbicort | $317 | $5,51321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in East Greenwich
- David FriedEast Greenwich$37.2M
- Todd ViccioneEast Greenwich$22K
- Jonathan MartinEast Greenwich$11K
- Gregory AllenCranston$12.2M
- Kathleen GordonJohnston$1.1M
- William BeliveauJohnson$962K
- Scott WilsonCumberland$907K
- Aaron SamuelsProvidence$751K
- Frank D'alessandroLincoln$541K
- Andrew HsuProvidence$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.